{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:20:31Z","timestamp":1782796831597,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS121038"],"award-info":[{"award-number":["R01NS121038"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R03NS099953"],"award-info":[{"award-number":["R03NS099953"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtm.2024.101347","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:56:48Z","timestamp":1727398608000},"page":"101347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design and validation of cell-based potency assays for frataxin supplementation treatments"],"prefix":"10.1016","volume":"32","author":[{"given":"Shibani","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Pereboeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achisha","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Grazia","family":"Cotticelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Soragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Napierala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5141-0822","authenticated-orcid":false,"given":"Jill S.","family":"Napierala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101347_bib1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.omtm.2024.101347_bib2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and genetic abnormalities in patients with Friedreich's ataxia","volume":"335","author":"Durr","year":"1996","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101347_bib3","first-page":"554","article-title":"The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia","volume":"59","author":"Filla","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2024.101347_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U","article-title":"Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes","volume":"45","author":"Cossee","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2024.101347_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ana.24595","article-title":"Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia","volume":"79","author":"Galea","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2024.101347_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fphar.2014.00130","article-title":"Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation","volume":"5","author":"Martelli","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtm.2024.101347_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtm.2024.101347_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41582-024-00957-9","article-title":"Approval of omaveloxolone for Friedreich ataxia","volume":"20","author":"Boesch","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtm.2024.101347_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2024.101347_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2019.02.001","article-title":"Therapeutic Prospects for Friedreich's Ataxia","volume":"40","author":"Zhang","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtm.2024.101347_bib11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.omtm.2020.04.018","article-title":"CRISPR-Cas9 Gene Editing of Hematopoietic Stem Cells from Patients with Friedreich's Ataxia","volume":"17","author":"Rocca","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101347_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101529","article-title":"Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich's ataxia cardiomyocytes","volume":"40","author":"Li","year":"2019","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.omtm.2024.101347_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101193","article-title":"AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich's ataxia","volume":"32","author":"Chang","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101347_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/acn3.51971","article-title":"Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich's ataxia","volume":"11","author":"Clayton","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2024.101347_bib17","doi-asserted-by":"crossref","first-page":"11492","DOI":"10.1073\/pnas.96.20.11492","article-title":"Deficit of in\u00a0vivo mitochondrial ATP production in patients with Friedreich ataxia","volume":"96","author":"Lodi","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101347_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.freeradbiomed.2020.07.019","article-title":"Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, Friedreich's ataxia","volume":"159","author":"Chiang","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.omtm.2024.101347_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102038","article-title":"Mechanisms of impaired mitochondrial homeostasis and NAD(+) metabolism in a model of mitochondrial heart disease exhibiting redox active iron accumulation","volume":"46","author":"Chiang","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.omtm.2024.101347_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/iub.2457","article-title":"Mitochondrial iron and calcium homeostasis in Friedreich ataxia","volume":"73","author":"Tamarit","year":"2021","journal-title":"IUBMB Life"},{"key":"10.1016\/j.omtm.2024.101347_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.838335","article-title":"Recent Advances in the Elucidation of Frataxin Biochemical Function Open Novel Perspectives for the Treatment of Friedreich's Ataxia","volume":"16","author":"Monfort","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtm.2024.101347_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.omtm.2020.03.013","article-title":"Development of an In\u00a0Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release","volume":"17","author":"Lengler","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101347_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jnc.12219","article-title":"Animal and cellular models of Friedreich ataxia","volume":"126","author":"Perdomini","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtm.2024.101347_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/bio.2015.0117","article-title":"Establishment and Maintenance of Primary Fibroblast Repositories for Rare Diseases-Friedreich's Ataxia Example","volume":"14","author":"Li","year":"2016","journal-title":"Biopreserv. Biobank."},{"key":"10.1016\/j.omtm.2024.101347_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijcard.2016.03.040","article-title":"Using human pluripotent stem cells to study Friedreich ataxia cardiomyopathy","volume":"212","author":"Crombie","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.omtm.2024.101347_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/21678707.2019.1562334","article-title":"Progress in understanding Friedreich's ataxia using human induced pluripotent stem cells","volume":"7","author":"Schreiber","year":"2019","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.omtm.2024.101347_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40035-023-00376-8","article-title":"Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application","volume":"12","author":"Maheshwari","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.omtm.2024.101347_bib28","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1093\/hmg\/ddaa267","article-title":"Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia","volume":"29","author":"Rodden","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101347_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147507","article-title":"Interruptions of the FXN GAA Repeat Tract Delay the Age at Onset of Friedreich's Ataxia in a Location Dependent Manner","volume":"22","author":"Nethisinghe","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101347_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2022.103385","article-title":"Replication dependent and independent mechanisms of GAA repeat instability","volume":"118","author":"Masnovo","year":"2022","journal-title":"DNA Repair"},{"key":"10.1016\/j.omtm.2024.101347_bib31","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1016\/j.molcel.2022.08.007","article-title":"S1-END-seq reveals DNA secondary structures in human cells","volume":"82","author":"Matos-Rodrigues","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtm.2024.101347_bib32","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/hmg\/ddt576","article-title":"Apoptotic cell death and altered calcium homeostasis caused by frataxin depletion in dorsal root ganglia neurons can be prevented by BH4 domain of Bcl-xL protein","volume":"23","author":"Mincheva-Tasheva","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101347_bib33","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/ijms15045789","article-title":"Frataxin silencing inactivates mitochondrial Complex I in NSC34 motoneuronal cells and alters glutathione homeostasis","volume":"15","author":"Carletti","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101347_bib34","article-title":"Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34","volume":"11","author":"Shen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101347_bib35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.30054","article-title":"Inducible and reversible phenotypes in a novel mouse model of Friedreich's Ataxia","volume":"6","author":"Chandran","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.omtm.2024.101347_bib36","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.045229","article-title":"Mitochondrial damage and senescence phenotype of cells derived from a novel frataxin G127V point mutation mouse model of Friedreich's ataxia","volume":"13","author":"Fil","year":"2020","journal-title":"Disease Models Mech."},{"key":"10.1016\/j.omtm.2024.101347_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.105996","article-title":"Neurobehavioral deficits of mice expressing a low level of G127V mutant frataxin","volume":"177","author":"Fil","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2024.101347_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020666","article-title":"Differential expression of PGC-1alpha and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts","volume":"6","author":"Garcia-Gimenez","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101347_bib39","doi-asserted-by":"crossref","first-page":"9840","DOI":"10.1038\/s41598-017-10320-2","article-title":"Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2024.101347_bib40","first-page":"4847","article-title":"Friedreich ataxia-induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor","volume":"25","author":"Codazzi","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101347_bib41","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/hum.2020.053","article-title":"Defining transcription regulatory elements in the human frataxin gene: implications for gene therapy","volume":"31","author":"Li","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101347_bib42","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","article-title":"Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance","volume":"82","author":"Elhamamsy","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2024.101347_bib43","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58461","article-title":"Manipulation of the human tRNA pool reveals distinct tRNA sets that act in cellular proliferation or cell cycle arrest","volume":"9","author":"Aharon-Hefetz","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.omtm.2024.101347_bib44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s42003-018-0239-8","article-title":"Global analysis of tRNA and translation factor expression reveals a dynamic landscape of translational regulation in human cancers","volume":"1","author":"Zhang","year":"2018","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtm.2024.101347_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/jcr.1925.148","article-title":"The metabolims of carcinoma cells","volume":"9","author":"Warburg","year":"1925","journal-title":"J.\u00a0Cancer Res."},{"key":"10.1016\/j.omtm.2024.101347_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbabio.2004.09.004","article-title":"P\/O ratios of mitochondrial oxidative phosphorylation","volume":"1706","author":"Hinkle","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtm.2024.101347_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.omtm.2024.101347_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s42255-020-0172-2","article-title":"We need to talk about the Warburg effect","volume":"2","author":"DeBerardinis","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.omtm.2024.101347_bib49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.tcb.2023.03.013","article-title":"The Warburg effect: a signature of mitochondrial overload","volume":"33","author":"Wang","year":"2023","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omtm.2024.101347_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1752-0509-4-58","article-title":"Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited","volume":"4","author":"Vazquez","year":"2010","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.omtm.2024.101347_bib51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ncb3124","article-title":"Metabolic pathways promoting cancer cell survival and growth","volume":"17","author":"Boroughs","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtm.2024.101347_bib52","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1126\/science.1193494","article-title":"The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes","volume":"330","author":"Levine","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtm.2024.101347_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ng1097-215","article-title":"Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia","volume":"17","author":"Rotig","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2024.101347_bib54","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/sj.embor.embor918","article-title":"An interaction between frataxin and Isu1\/Nfs1 that is crucial for Fzxc e\/S cluster synthesis on Isu1","volume":"4","author":"Gerber","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtm.2024.101347_bib55","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1038\/ncomms6686","article-title":"Mammalian frataxin directly enhances sulfur transfer of NFS1 persulfide to both ISCU and free thiols","volume":"6","author":"Parent","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2024.101347_bib56","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/s41467-019-09989-y","article-title":"Structure of the human frataxin-bound iron-sulfur cluster assembly complex provides insight into its activation mechanism","volume":"10","author":"Fox","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2024.101347_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1242\/dmm.009019","article-title":"Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease","volume":"5","author":"Rouault","year":"2012","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2024.101347_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.2093","article-title":"Frataxin deficiency alters gene expression in Friedreich ataxia derived IPSC-neurons and cardiomyocytes","volume":"11","author":"Angulo","year":"2023","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.omtm.2024.101347_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107713","article-title":"Butyrate prevents visceral adipose tissue inflammation and metabolic alterations in a Friedreich's ataxia mouse model","volume":"26","author":"Turchi","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.omtm.2024.101347_bib60","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202402609","article-title":"Frataxin deficiency shifts metabolism to promote reactive microglia via glucose catabolism","volume":"7","author":"Sciarretta","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omtm.2024.101347_bib61","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/ncomms3935","article-title":"Tumour-associated mutant p53 drives the Warburg effect","volume":"4","author":"Zhang","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2024.101347_bib62","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1158\/1078-0432.CCR-14-1209","article-title":"Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA","volume":"21","author":"Ooi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2024.101347_bib63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:05:55Z","timestamp":1737666355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124001633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2329050124001633"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101347","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and validation of cell-based potency assays for frataxin supplementation treatments","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101347"}}